Clinical trial · Interventional
Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.
Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): difficulties to recruit patients
Summary
Brief summary (as posted)
The indications liver cancer surgery currently booming due to the increase in surgical techniques and instruments for a more secure resection of liver tissue with a significant reduction in bleeding or surgical complications. This allowed to expand surgical indications in the most fragile patients so assuming optimized anesthetic care. So far, the technique of analgesia reference to this surgery remains administration of morphine analgesia via a device controlled by the patient (PCA) for epidural analgesia is against-indicated because of induced bleeding disorders by surgery. Rafi then McDonnell in 2007 have described a new technique of loco regional anesthesia, the abdomen of the Transversus Abdominis Plane (TAP) nerve block(TAP), which allows selective anesthesia of the abdominal wall. But parietal pain related muscular and nervous sagging surgical approach represent a significant share of post operative pain. This study proposes an evaluation of the abdomen transverse blocks in hepatectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer, Adult | Malignant Liver Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Drug | — | UNRESOLVED |
| RopivacaIne chlorhydrate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ropivacaïne chlorhydrate monohydrate
- interventionNames
- Drug: RopivacaIne chlorhydrate
- type
- PLACEBO_COMPARATOR
- label
- placebo
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- consumption of morphine over the first 48 hours postoperative.
- timeFrame
- at 48 hours postoperative
Secondary outcomes (1)
- measure
- pharmacokinetic of ropivacaine (plasma concentrations)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * hepatectomy or segmentectomy Exclusion Criteria: * Sepsis uncontrolled current * Overdose in anticoagulant during general anesthesia * Thrombocytopenia \<50 g / dl * Severe renal impairment: Cockcroft \<30 ml / min * history of ventricular arrhythmia serious unexplained .\* * Allergy to local anesthetics of the amide * Contraindication to remifentanil and morphine * Hypovolemia
References
Publications (0)
Data not yet available